General Biotechnology

Fix Pharma Forecasts: Common Misinterpretations of the FDA Orange Book That Distort Market Forecasts

FDA Orange Book: The “Truth” That Isn’t—How Forecasts Get Skewed Before They Start
Most market forecasts don’t fail because the math is wrong. They fail because the inputs are.
In a recent post, DrugPatentWatch highlights a pattern that’s become all to…

Fix Pharma Forecasts: Common Misinterpretations of the FDA Orange Book That Distort Market Forecasts Read Post »

General Biotechnology

Stop Patent Hops: Detecting “Evergreening” Patterns Through Sequential FDA Orange Book Listings

🚨 Patent “evergreening” isn’t always a single blockbuster lawsuit. Often, it’s a pattern—quiet, procedural, and repeatable.
In a recent post, DrugPatentWatch breaks down how to spot one of the most important signals in pharma IP strategy: sequential…

Stop Patent Hops: Detecting “Evergreening” Patterns Through Sequential FDA Orange Book Listings Read Post »

Biotechblog
Scroll to Top